论文部分内容阅读
目的:比较长春瑞滨联合顺铂或奈达铂治疗晚期非小细胞肺癌(N SCLC)的疗效及不良反应。方法:67例患者随机分成试验组(长春瑞滨加奈达铂)和对照组(长春瑞滨加顺铂)。结果:两组有效率、中位生存时间及1、2 a生存率均无显著差异(P>0.05)。试验组消化道反应发生率显著低于对照组(P<0.05),余不良反应无显著差异(P>0.05)。结论:两组疗效相似,但试验组不良反应较轻。
OBJECTIVE: To compare the efficacy and adverse reactions of vinorelbine plus cisplatin or nedaplatin in the treatment of advanced non-small cell lung cancer (N SCLC). Methods: Sixty-seven patients were randomly divided into experimental group (vinorelbine plus nareplatin) and control group (vinorelbine plus cisplatin). Results: There was no significant difference between the two groups in the effective rate, median survival time and 1,2-year survival rate (P> 0.05). The incidence of digestive tract reaction in the experimental group was significantly lower than that in the control group (P <0.05), with no significant difference in adverse reactions (P> 0.05). Conclusion: The two groups have similar curative effect, but the adverse reaction in the test group is lighter.